Expanding its Southeast Asian Footprint, Tongee Medical's Gastric Bypass Stent System Has Obtained the Medical Device Registration Certificate in Singapore!

‍Recently, the gastric bypass stent system independently developed by Tongee Medical has officially been approved for marketing by the HSA of Singapore. This is the sixth country in Southeast Asia to approve the system after Indonesia, Thailand, Vietnam, Malaysia and the Philippines, marking a further improvement in Tongee Medical's strategic layout in the Southeast Asian market and a further acceleration of its globalization process.

As a medical innovation hub in Southeast Asia, Singapore boasts a globally leading medical regulatory system and strict market access standards. This approval not only reflects the high recognition of the safety, efficacy and quality control system of the gastric bypass stent system by the Singaporean health authorities, but also marks the official entry of this Chinese-originated intestinal interventional weight loss technology into the high-end medical market in Southeast Asia.

By now, Tongee Medical has achieved full coverage of the major economies in Southeast Asia - from populous countries like Indonesia and the Philippines to the medical benchmark Singapore, establishing a complete and widely radiating regional market network. This has laid a solid foundation for the large-scale promotion of this technology in the Southeast Asian region.

Starting from its domestic approval for listing in 2024, to obtaining the "Breakthrough Medical Device Recognition" from the US FDA, and then expanding to cover countries along the "Belt and Road Initiative" such as Southeast Asia, the Middle East, and South America - Tongee Medical is advancing its original Chinese metabolic disease solutions to the world with solid steps.

In the future, Tongee Medical will continue to deepen its strategic cooperation with medical institutions in Southeast Asian countries, accelerate the clinical training and standardized application of the gastric bypass stent system, and strive to build an international metabolic health management ecosystem centered on the gastric bypass stent and featuring multi-product collaboration. This will empower the upgrading of global obesity and metabolic disease diagnosis and treatment levels, enabling original and innovative medical achievements to benefit more patients worldwide, and demonstrating the global responsibility and industry commitment of Chinese medical enterprises.

‍